Bolt Biotherapeutics, Inc. Operating Lease Cost
Bolt Biotherapeutics, Inc. (BOLT) reported Operating Lease Cost of $903.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $903.00K, a 8.51% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $945.00K, a 15.32% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $963.00K, a 38.43% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $978.00K, a 12.60% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, cost for fiscal 2025 was $4.00M, a 18.63% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. operating lease, cost for fiscal 2024 was $4.92M, a 9.87% increase from fiscal 2023.
- Bolt Biotherapeutics, Inc. operating lease, cost for fiscal 2023 was $4.48M, a 3.08% increase from fiscal 2022.
- Bolt Biotherapeutics, Inc. operating lease, cost for fiscal 2022 was $4.35M, a 13.12% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $903.00K 10-Q · filed 2026-08-11 | $1.85M 10-Q · filed 2026-08-11 | $2.81M derived: sum of 3 quarters · filed 2026-08-11 | $3.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $945.00K 10-Q · filed 2026-05-12 | $1.91M derived: sum of 2 quarters · filed 2026-05-12 | $2.89M derived: sum of 3 quarters · filed 2026-05-12 | $3.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $963.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.94M derived: sum of 2 quarters · filed 2026-03-12 | $2.93M derived: sum of 3 quarters · filed 2026-08-11 | $4.00M 10-K · filed 2026-03-12 |
| 2025-09-30 | $978.00K 10-Q · filed 2025-11-12 | $1.97M derived: sum of 2 quarters · filed 2026-08-11 | $3.04M 10-Q · filed 2025-11-12 | $4.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $987.00K 10-Q · filed 2026-08-11 | $2.06M 10-Q · filed 2026-08-11 | $3.67M derived: sum of 3 quarters · filed 2026-08-11 | $4.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.12M 10-Q · filed 2026-05-12 | $2.68M derived: sum of 2 quarters · filed 2026-05-12 | $3.80M derived: sum of 3 quarters · filed 2026-05-12 | $4.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.68M derived: sum of 2 quarters · filed 2026-03-12 | $3.80M derived: sum of 3 quarters · filed 2026-03-12 | $4.92M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.12M 10-Q · filed 2025-11-12 | $2.24M derived: sum of 2 quarters · filed 2025-11-12 | $3.36M 10-Q · filed 2025-11-12 | $4.48M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.12M 10-Q · filed 2025-08-14 | $2.24M 10-Q · filed 2025-08-14 | $3.36M derived: sum of 3 quarters · filed 2025-08-14 | $4.48M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.12M 10-Q · filed 2025-05-12 | $2.24M derived: sum of 2 quarters · filed 2025-05-12 | $3.36M derived: sum of 3 quarters · filed 2025-05-12 | $4.48M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.24M derived: sum of 2 quarters · filed 2025-03-24 | $3.36M derived: sum of 3 quarters · filed 2025-03-24 | $4.48M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.12M 10-Q · filed 2024-11-12 | $2.24M derived: sum of 2 quarters · filed 2024-11-12 | $3.36M 10-Q · filed 2024-11-12 | $4.48M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.12M 10-Q · filed 2024-08-13 | $2.24M 10-Q · filed 2024-08-13 | $3.36M derived: sum of 3 quarters · filed 2024-08-13 | $4.41M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.12M 10-Q · filed 2024-05-14 | $2.24M derived: sum of 2 quarters · filed 2024-05-14 | $3.29M derived: sum of 3 quarters · filed 2024-05-14 | $4.33M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.17M derived: sum of 2 quarters · filed 2024-03-21 | $3.21M derived: sum of 3 quarters · filed 2024-03-21 | $4.35M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.05M 10-Q · filed 2023-11-09 | $2.09M derived: sum of 2 quarters · filed 2023-11-09 | $3.23M 10-Q · filed 2023-11-09 | $4.35M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.04M 10-Q · filed 2023-08-07 | $2.17M 10-Q · filed 2023-08-07 | $3.30M derived: sum of 3 quarters · filed 2023-08-07 | $4.53M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $1.13M 10-Q · filed 2023-05-11 | $2.25M derived: sum of 2 quarters · filed 2023-05-11 | $3.48M derived: sum of 3 quarters · filed 2023-05-11 | $4.39M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $2.35M derived: sum of 2 quarters · filed 2023-03-29 | $3.25M derived: sum of 3 quarters · filed 2023-03-29 | $3.84M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.23M 10-Q · filed 2022-11-10 | $2.13M derived: sum of 2 quarters · filed 2022-11-10 | $2.72M 10-Q · filed 2022-11-10 | $3.38M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $902.00K 10-Q · filed 2022-08-10 | $1.67M 10-Q · filed 2022-08-10 | $2.15M derived: sum of 3 quarters · filed 2022-08-10 | $2.88M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $664.00K 10-Q · filed 2022-05-12 | $1.25M derived: sum of 2 quarters · filed 2022-05-12 | $1.98M derived: sum of 3 quarters · filed 2022-05-12 | $2.58M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.31M derived: sum of 2 quarters · filed 2022-03-30 | $1.92M derived: sum of 3 quarters · filed 2022-03-30 | $2.51M 10-K · filed 2022-03-30 |
| 2020-09-30 | $724.00K 10-Q · filed 2021-11-09 | $1.33M derived: sum of 2 quarters · filed 2021-11-09 | $1.92M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $603.00K 10-Q · filed 2021-08-12 | $1.20M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $593.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |